“…(i) Through several passages, the phenotypic properties of the HCECs and their sensitivity to toxic agents can change. (ii) In the anterior chamber, multiple mechanisms exist that protect the corneal endothelium (e.g., epithelial, fibroblast, and platelet-derived growth factors) (36). (iii) Due to metabolism in the anterior chamber, the intracameral voriconazole concentration conceivably decreases gradually; thus, exposure to sustained high concentrations of the drug for 24 h may not be common in in vivo conditions.…”